Commentary - Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer's disease and to identify high-risk subgroups

被引:52
作者
Lehmann, DJ
Williams, J
McBroom, J
Smith, AD
机构
[1] Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England
[2] Radcliffe Infirm, OPTIMA, Oxford OX2 6HE, England
[3] Univ Oxford, Dept Stat, Oxford OX1 3TG, England
关键词
apolipoprotein E epsilon 4; butyrylcholinesterase K; meta-analysis; association; case-control; susceptibility;
D O I
10.1016/S0306-4522(01)00464-X
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In late-onset Alzheimer's disease, there is a puzzling inconsistency between the findings of case-control studies of most proposed risk genes, except apolipoprotein E epsilon4. This inconsistency may stem from the failure to define the genetic and non-genetic interactions that affect the disease association of each particular susceptibility gene. Such interactions will limit the influence of the gene to a 'relevant subset' of vulnerable people, The relevant subsets for many risk genes will be narrow, compared to that of apolipoprotein E epsilon4. Studies may therefore miss the association or even suggest that a risk gene is protective. In these circumstances, the precise composition of a cohort is critical and defining the relevant subset is crucial. We illustrate how such definition may be achieved through meta-analysis. We take as an example the butyrylcholinesterase K variant, whose association with Alzheimer's disease may now be provisionally defined. This analysis leads to the identification of it potentially high-risk group: over 75 year old male carriers of both apolipoprotein E epsilon4 and butyrylcholinesterase K variant. (C) 2001 IBRO. Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:541 / 554
页数:14
相关论文
共 104 条
  • [1] Genetic polymorphisms and disease
    Altshuler, D
    Kruglyak, L
    Lander, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (22) : 1626 - 1626
  • [2] American Psychiatric Association, 1987, DSM 3 R DIAGNOSTIC S, V3rd
  • [3] [Anonymous], NEUROBIOL AGING
  • [4] ARMITAGE P, 1983, STAT METHODS MED RES
  • [5] Bergem ALM, 1997, ARCH GEN PSYCHIAT, V54, P264
  • [6] Candidate genes showing no evidence for association or linkage with Alzheimer's disease using family-based methodologies
    Bertram, L
    Blacker, D
    Crystal, A
    Mullin, K
    Keeney, D
    Jones, J
    Basu, S
    Yhu, S
    Guénette, S
    McInnis, M
    Go, R
    Tanzi, R
    [J]. EXPERIMENTAL GERONTOLOGY, 2000, 35 (9-10) : 1353 - 1361
  • [7] APO-E-ALLELE FREQUENCIES IN ALZHEIMERS-DISEASE, LEWY BODY DEMENTIA, ALZHEIMERS-DISEASE WITH CEREBROVASCULAR-DISEASE AND VASCULAR DEMENTIA
    BETARD, C
    ROBITAILLE, Y
    GEE, M
    TIBERGHIEN, D
    LARRIVEE, D
    ROY, P
    MORTIMER, JA
    GAUVREAU, D
    [J]. NEUROREPORT, 1994, 5 (15) : 1893 - 1896
  • [8] Analysis of the butyrylcholinesterase gene and nearby chromosome 3 markers in Alzheimer disease
    Brindle, N
    Song, Y
    Rogaeva, E
    Premkumar, S
    Levesque, G
    Yu, G
    Ikeda, M
    Nishimura, M
    Paterson, A
    Sorbi, S
    Duara, R
    Farrer, L
    St George-Hyslop, P
    [J]. HUMAN MOLECULAR GENETICS, 1998, 7 (05) : 933 - 935
  • [9] A pharmacogenomic approach to Alzheimer's disease
    Cacabelos, R
    Alvarez, A
    Fernández-Novoa, L
    Lombardi, VRM
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 2000, 102 : 12 - 19
  • [10] APOLIPOPROTEIN-E, EPSILON-4 ALLELE AS A MAJOR RISK FACTOR FOR SPORADIC EARLY AND LATE-ONSET FORMS OF ALZHEIMERS-DISEASE - ANALYSIS OF THE 19Q13.2 CHROMOSOMAL REGION
    CHARTIERHARLIN, MC
    PARFITT, M
    LEGRAIN, S
    PEREZTUR, J
    BROUSSEAU, T
    EVANS, A
    BERR, C
    VIDAL, O
    ROQUES, P
    GOURLET, V
    FRUCHART, JC
    DELACOURTE, A
    ROSSOR, M
    AMOUYEL, P
    [J]. HUMAN MOLECULAR GENETICS, 1994, 3 (04) : 569 - 574